Novo Nordisk A/S
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Novo Nordisk A/S published this content on August 31, 2025 , and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) , unedited and unaltered, on August 31, 2025 at 12:58 UTC .
